Vigilant Capital Management LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 249,577 shares of the healthcare product maker’s stock after selling 5,184 shares during the period. Abbott Laboratories comprises about 2.8% of Vigilant Capital Management LLC’s holdings, making the stock its 5th biggest position. Vigilant Capital Management LLC’s holdings in Abbott Laboratories were worth $20,989,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABT. Bank OZK increased its stake in shares of Abbott Laboratories by 0.5% during the first quarter. Bank OZK now owns 24,326 shares of the healthcare product maker’s stock valued at $1,944,000 after buying an additional 133 shares during the period. CX Institutional boosted its position in Abbott Laboratories by 1.6% during the second quarter. CX Institutional now owns 8,777 shares of the healthcare product maker’s stock valued at $738,000 after purchasing an additional 136 shares in the last quarter. First Command Bank boosted its position in Abbott Laboratories by 2.5% during the first quarter. First Command Bank now owns 6,101 shares of the healthcare product maker’s stock valued at $488,000 after purchasing an additional 146 shares in the last quarter. Pinkerton Retirement Specialists LLC boosted its position in Abbott Laboratories by 0.3% during the fourth quarter. Pinkerton Retirement Specialists LLC now owns 49,500 shares of the healthcare product maker’s stock valued at $3,580,000 after purchasing an additional 147 shares in the last quarter. Finally, Annex Advisory Services LLC boosted its holdings in Abbott Laboratories by 1.0% in the fourth quarter. Annex Advisory Services LLC now owns 15,089 shares of the healthcare product maker’s stock worth $1,091,000 after acquiring an additional 150 shares in the last quarter. Institutional investors and hedge funds own 73.42% of the company’s stock.

Shares of Abbott Laboratories stock traded down $0.45 on Tuesday, reaching $88.10. 126,382 shares of the stock were exchanged, compared to its average volume of 4,552,908. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.58 and a quick ratio of 1.13. Abbott Laboratories has a twelve month low of $63.07 and a twelve month high of $88.76. The company has a market capitalization of $154.81 billion, a price-to-earnings ratio of 30.60, a price-to-earnings-growth ratio of 2.47 and a beta of 1.10. The company has a 50 day simple moving average of $84.88.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, July 17th. The healthcare product maker reported $0.82 EPS for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.02. Abbott Laboratories had a return on equity of 17.39% and a net margin of 9.36%. The firm had revenue of $7.98 billion during the quarter, compared to the consensus estimate of $8 billion. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s revenue was up 2.7% compared to the same quarter last year. On average, research analysts predict that Abbott Laboratories will post 3.24 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Monday, July 15th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.45%. The ex-dividend date of this dividend is Friday, July 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 44.44%.

Several equities research analysts have weighed in on ABT shares. Cowen reissued a “buy” rating and issued a $184.00 price target on shares of Union Pacific in a report on Thursday, July 18th. William Blair reissued an “outperform” rating on shares of Abbott Laboratories in a report on Thursday, April 18th. Zacks Investment Research downgraded Home Bancshares from a “hold” rating to a “sell” rating in a report on Friday, June 7th. Royal Bank of Canada raised their price target on Alimentation Couche-Tard from C$85.00 to C$88.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Finally, Morgan Stanley lowered their price target on Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a report on Tuesday, July 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $85.82.

In related news, EVP Daniel Gesua Sive Salvadori sold 71,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $84.00, for a total transaction of $5,964,000.00. Following the completion of the transaction, the executive vice president now directly owns 167,148 shares in the company, valued at $14,040,432. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Randel William Woodgrift sold 65,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $88.01, for a total value of $5,720,650.00. Following the transaction, the insider now owns 117,562 shares of the company’s stock, valued at $10,346,631.62. The disclosure for this sale can be found here. Insiders have sold 1,125,260 shares of company stock valued at $89,443,361 in the last ninety days. Corporate insiders own 0.70% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Recommended Story: Trading Ex-Dividend

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.